Literature DB >> 24294503

Intensifying local radiotherapy for pancreatic cancer-who benefits and how do we select them?

Sunil Krishnan1, Mediha Ahmad.   

Abstract

Entities:  

Year:  2013        PMID： 24294503      PMCID： PMC3819774          DOI： 10.3978/j.issn.2078-6891.2013.027

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN： 2078-6891


× No keyword cloud information.
  10 in total

Review 1.  Treatment of locally advanced pancreatic cancer: the role of radiation therapy.

Authors:  Kimberly Johung; Muhammad Wasif Saif; Bryan W Chang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-11-09       Impact factor: 7.038

2.  Preoperative chemoradiation and IOERT for unresectable or borderline resectable pancreas cancer.

Authors:  Jonathan B Ashman; Adyr A Moss; William G Rule; Matthew G Callister; K Sudhakar Reddy; David C Mulligan; Joseph M Collins; Giovanni De Petris; Leonard L Gunderson; Mitesh Borad
Journal:  J Gastrointest Oncol       Date:  2013-12

3.  Are mammographic changes in the tumor bed more pronounced after intraoperative radiotherapy for breast cancer? Subgroup analysis from a randomized trial (TARGIT-A).

Authors:  Dorothee Engel; Andreas Schnitzer; Joachim Brade; Elena Blank; Frederik Wenz; Marc Suetterlin; Stefan Schoenberg; Klaus Wasser
Journal:  Breast J       Date:  2012-11-23       Impact factor: 2.431

4.  Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression.

Authors:  Christopher H Crane; Gauri R Varadhachary; John S Yordy; Gregg A Staerkel; Milind M Javle; Howard Safran; Waqar Haque; Bridgett D Hobbs; Sunil Krishnan; Jason B Fleming; Prajnan Das; Jeffrey E Lee; James L Abbruzzese; Robert A Wolff
Journal:  J Clin Oncol       Date:  2011-06-27       Impact factor: 44.544

5.  Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial.

Authors:  Jayant S Vaidya; David J Joseph; Jeffrey S Tobias; Max Bulsara; Frederik Wenz; Christobel Saunders; Michael Alvarado; Henrik L Flyger; Samuele Massarut; Wolfgang Eiermann; Mohammed Keshtgar; John Dewar; Uta Kraus-Tiefenbacher; Marc Sütterlin; Laura Esserman; Helle M R Holtveg; Mario Roncadin; Steffi Pigorsch; Marinos Metaxas; Mary Falzon; April Matthews; Tammy Corica; Norman R Williams; Michael Baum
Journal:  Lancet       Date:  2010-07-10       Impact factor: 79.321

6.  Intraoperative radiotherapy--past, present and future.

Authors:  M Abe
Journal:  Int J Radiat Oncol Biol Phys       Date:  1984-10       Impact factor: 7.038

7.  Intraoperative radiotherapy for resected pancreatic cancer: a multi-institutional retrospective analysis of 210 patients.

Authors:  Kazuhiko Ogawa; Katsuyuki Karasawa; Yoshinori Ito; Yoshihiro Ogawa; Keiichi Jingu; Hiroshi Onishi; Shinichi Aoki; Hitoshi Wada; Masaki Kokubo; Hidehiro Etoh; Tomoko Kazumoto; Makoto Takayama; Yoshiharu Negoro; Kenji Nemoto; Yasumasa Nishimura
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-03-06       Impact factor: 7.038

8.  DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer.

Authors:  Christine A Iacobuzio-Donahue; Baojin Fu; Shinichi Yachida; Mingde Luo; Hisashi Abe; Clark M Henderson; Felip Vilardell; Zheng Wang; Jesse W Keller; Priya Banerjee; Joseph M Herman; John L Cameron; Charles J Yeo; Marc K Halushka; James R Eshleman; Marian Raben; Alison P Klein; Ralph H Hruban; Manuel Hidalgo; Daniel Laheru
Journal:  J Clin Oncol       Date:  2009-03-09       Impact factor: 44.544

9.  Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy.

Authors:  Sunil Krishnan; Vishal Rana; Nora A Janjan; Gauri R Varadhachary; James L Abbruzzese; Prajnan Das; Marc E Delclos; Morris S Gould; Douglas B Evans; Robert A Wolff; Christopher H Crane
Journal:  Cancer       Date:  2007-07-01       Impact factor: 6.860

Review 10.  Normal tissue tolerance to intraoperative radiotherapy.

Authors:  William F Sindelar; Timothy J Kinsella
Journal:  Surg Oncol Clin N Am       Date:  2003-10       Impact factor: 3.495
  10 in total
  3 in total

1.  Exploiting Arginine Auxotrophy with Pegylated Arginine Deiminase (ADI-PEG20) to Sensitize Pancreatic Cancer to Radiotherapy via Metabolic Dysregulation.

Authors:  Pankaj K Singh; Amit A Deorukhkar; Bhanu P Venkatesulu; Xiaolin Li; Ramesh Tailor; John S Bomalaski; Sunil Krishnan
Journal:  Mol Cancer Ther       Date:  2019-08-08       Impact factor: 6.261

2.  Intraoperative Radiation "Boost" to the Surgical Resection Bed following Pancreaticoduodenectomy for a Borderline Resectable Pancreatic Carcinoma: A Case Report.

Authors:  Tarita O Thomas; William Small; Mark Fleming; Song Kang; Richard A Hoefer
Journal:  Front Oncol       Date:  2018-03-23       Impact factor: 6.244

3.  The role of intraoperative radiation therapy in resectable pancreatic cancer: a systematic review and meta-analysis.

Authors:  Liang Jin; Ning Shi; Shiye Ruan; Baohua Hou; Yiping Zou; Xiongfeng Zou; Haosheng Jin; Zhixiang Jian
Journal:  Radiat Oncol       Date:  2020-04-09       Impact factor: 3.481
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.